Ticagrelor: Difference between revisions
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
{{Drugbox | {{Drugbox | ||
| IUPAC_name = (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol | | IUPAC_name = (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol | ||
| CAS_number = 274693-27-5 | | CAS_number = 274693-27-5 | ||
| CAS_supplemental = | | CAS_supplemental = | ||
Line 62: | Line 61: | ||
{{SIB}} | {{SIB}} | ||
{{Template:Antithrombotics}} | |||
== References == | == References == | ||
{{reflist}} | {{reflist}} | ||
[[Category:ADP receptor inhibitors]] | [[Category:ADP receptor inhibitors]] |
Revision as of 14:31, 10 September 2009
Clinical data | |
---|---|
Routes of administration | oral |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C23H28F2N6O4S |
Molar mass | 522.567 g/mol |
3D model (JSmol) | |
|
WikiDoc Resources for Ticagrelor |
Articles |
---|
Most recent articles on Ticagrelor |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Ticagrelor at Clinical Trials.gov Clinical Trials on Ticagrelor at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Ticagrelor
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Ticagrelor Discussion groups on Ticagrelor Patient Handouts on Ticagrelor Directions to Hospitals Treating Ticagrelor Risk calculators and risk factors for Ticagrelor
|
Healthcare Provider Resources |
Causes & Risk Factors for Ticagrelor |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Ticagrelor (AZD6140) is a platelet aggregation inhibitor produced by AstraZeneca. As of February 2008[update], a clinical trial (PLATO: Platelet inhibition and patient outcomes) is comparing a combination of ticagrelor plus aspirin to clopidogrel plus aspirin for the prevention of thromboembolism.
Method of action
Like clopidogrel and ticlopidine, ticagrelor blocks ADP receptors of subtype P2Y12. In contrast to the other antiplatelet drugs, the blockage is reversible. Moreover, it does not need hepatic activation, which could reduce the risk of drug interactions.[1][2]
PLATO trial
This trial, recently published in New England Journal of Medicine, has confirmed the superiority of ticagrelor over clopidogel in patients with acute coronary syndromes.[3]
References
- ↑ H. Spreitzer (February 4, 2008). "Neue Wirkstoffe - AZD6140". Österreichische Apothekerzeitung (in German) (3/2008): 135. Check date values in:
|date=
(help) - ↑ Owen, RT, Serradell, N, Bolos, J (2007). "AZD6140". Drugs of the Future. 32 (10): 845–853. doi:10.1358/dof.2007.032.10.1133832.
- ↑ Wallentin, Lars (August 30, 2009). "Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes". NEJM.
- Pages with script errors
- CS1 errors: dates
- CS1 maint: Unrecognized language
- CS1 maint: Multiple names: authors list
- Drugs not assigned an ATC code
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Articles containing potentially dated statements from February 2008
- Articles with invalid date parameter in template
- All articles containing potentially dated statements
- ADP receptor inhibitors